



## International Journal of Allied Medical Sciences and Clinical Research (IJAMSCR)

IJAMSCR | Volume 3 | Issue 3 | July-Sep- 2015  
www.ijamscr.com

ISSN: 2347-6567

Review article

Medical research

### Anti-retroviral therapy induced adverse effects and its management: A brief review

Kandimalla.Chaitanya\*, Minu K. George, Bandlamudi.Yasaswini, Sudhakar.R

<sup>1</sup>Pharm. D intern, Department of Pharmacy Practice, Nandha College of Pharmacy, Erode, India.

Corresponding Author: Kandimalla.Chaitanya

Email-Chaitusoujikandimalla@gmail.com

#### ABSTRACT

The introduction and the widespread use of Highly Active Anti-Retroviral Therapy (HAART) dramatically changed the perspective of Human Immunodeficiency Virus (HIV) which leads to substantial decrease in morbidity and mortality rates. It is now the standard care of therapy includes 15 antiretroviral drugs available in four different drug classes, adverse effects vary from drug to drug and patient to patient. Hence, choosing between many of these combinations requires the adequate knowledge about Anti-Retroviral Therapy toxicities. The basic purpose of Anti-Retroviral Therapy is to maintain the quality of life of patients, but it is difficult to continue for prolonged duration because of problem with adherence and adverse-effects. This review mainly highlights the various classes of Anti-Retroviral Therapy, associated adverse effects, possible mechanisms and their effective management in order to improve adherence and quality of life.

**Key words:** Highly active Anti-Retroviral Therapy, Nucleoside Reverse Transcriptase Inhibitors, Non-nucleoside Reverse Transcriptase Inhibitors, PIS, Entry and Fusion Inhibitors.

#### INTRODUCTION

HIV/AIDS have been significant public health concerns and the epidemic continues to challenge humanity for over twenty years<sup>(1)</sup>. Immune system of our body plays an important role to protect us from various kinds of infections and diseases<sup>(2)</sup>. India is one of the most populated countries in the world, around 2.4 million people living with HIV. In 2007, globally there were an estimated 33million [30.3million-36.1million] people are living with HIV worldwide; 10.6 million were receiving ART in 2012.<sup>(3, 4, 5)</sup> The introduction of highly active antiretroviral therapy (HAART) in 1990, leads to the significant reduction in AIDS related morbidity and mortality, it contains the combination of 3 therapeutic

agents which includes 2 Nucleoside Reverse Transcriptase Inhibitors (NRTI) with a protease inhibitor (PI), with a non-nucleosidal reverse transcriptase inhibitor (NNRTI) or a third NRTI constitutes the HAART regimen<sup>(6,7)</sup>. The goal of HAART therapy has been to achieve sustained viral suppression, increased CD4 cell count, minimize drug resistance, and simply dosage pattern<sup>(8)</sup>. Approximately, up to 25% of patients discontinued initial HAART therapy with in the first 8 months due to treatment failure, severe adverse drug effects, non-adherence<sup>(9,10)</sup>. A study conducted by Radhakrishnan rajesh *et al.*, found that anemia and hepatotoxicity were the most commonly observed ADRs. The organ system commonly affected by ADR was red blood

cell (21.4%). The ADRs were moderate in 77% of cases. Type A reactions (77%) were common. 10.8% were definitely preventable. The incidence rate of ADRs (65.9%) was highest with Zidovudine+Lamivudine+Nevirapine combination<sup>(11)</sup>. Identification and awareness of ART toxicity by health care professionals is necessary to facilitate patient adherence and to determine the need in change of therapy like adjustments in dose, dosing frequency and duration of therapy<sup>(12)</sup>. Periodic monitoring of patients undergoing treatment with ART drugs is needed to minimize drug related complications.

### **Nucleoside reverse transcriptase inhibitors (NRTIS)**

The NRTIs are the 'back-bone' of Anti-Retroviral therapy which includes Zidovudine, Lamivudine, Didanosine, Stavudine, Abacavir and the newly released Tenofovir<sup>(4, 9)</sup>. NRTIs acts by inhibiting the HIV reverse transcriptase enzyme and terminate proviral DNA chain elongation. It inhibits not only viral reverse transcriptase but also cellular DNA polymerase which leads to mitochondrial toxicity and anaemia. The other common ADRs due to NRTIs include nausea, malaise, myalgia, insomnia and headache<sup>(13, 14)</sup>.

#### **Zidovudine induced anaemia**

Anaemia is a condition in which the number of red blood cells count is low. Anaemia and Neutropenia are the major toxicities associated with Zidovudine containing regimen of which anaemia has been reported in 5.4- 34.5 % of patients<sup>(15)</sup>. The exact mechanism of ZDV-induced anaemia is still unknown. It is mainly attributable to inhibition of proliferation of blood cell progenitor cells in a time and dose-dependent fashion. Anaemia is clearly presented after 4 weeks of Zidovudine therapy and the high prevalence starts from 4-24 weeks, which is related to impaired erythrocyte maturation results in macrocytosis in patients with lower baseline CD4 lymphocyte count, haemoglobin concentration and granulocyte count. ZDV induced anaemia can be effectively managed with Iron supplements, folic acid (Vit B12), or Blood transfusions. Based on its severity and Hb level should be monitored for the

first few months of ART regimen initiated with ZDV and then checked for every 6 months<sup>(15,16,17)</sup>.

#### **Stavudine induced lactic acidosis**

Lactic acidosis is a form of metabolic acidosis due to inadequate clearance of lactic acid from the blood. Compared to all NRTIs, Stavudine appears to cause lactic acidemia more frequently<sup>(18, 19, 20)</sup>. Stavudine induced lactic acidosis has been reported in 1.5-2.5% of patients taking NRTIs. Other side effects include peripheral neuropathy, headache, diarrhoea and allergic manifestations which are reported less frequently<sup>(21, 22)</sup>. The mechanism involved in Stavudine induced lactic acidosis is due to the inhibition of mitochondrial DNA poly merase- $\gamma$ , leading to depletion of mtDNA and diminished capacity of oxidative phosphorylation system<sup>(23)</sup>. Patients on long-term Stavudine therapy often complaints as loss of appetite, fatigue, nausea, weight loss, must be tested for levels of venous lactate to detect the early stage of symptomatic hyperlactatemia to avoid fatal complications such as lactic acidosis by prompt withdrawal of drug and timely management. Administering Riboflavin (vitamin B2), Ubiquinone (coenzyme Q10) and Thiamine at an earlier stage shows significant clinical benefit in HIV infected patients with lactic acidemia<sup>(24)</sup>.

#### **Non-nucleoside reverse transcriptase inhibitors (NNRTIS)**

Currently US Food and Drug administration approved five NNRTIs (Nevirapine, Delavirdine, Etravirine, Rilpivirine) of which Nevirapine and Efavirenz has been used as first-line antiretroviral therapy since 2002<sup>(25)</sup>. They acts by reducing HIV-1 replication by inhibiting the viral reverse transcriptase enzyme by binding to hydrophobic pocket located close to the enzymes catalytic site and inducing conformational changes that effect the catalytic activities of the enzymes<sup>(26)</sup>. The common side effects includes increased transaminase levels, headache, diarrhoea, nausea and skin rashes, Steven Johnson syndrome and hepatotoxicity were more observed in treatment with Nevirapine<sup>(11,27)</sup>.

#### **Nevirapine induced hepatotoxicity**

Hepatotoxicity can be defined as an injury to the liver usually associated with impaired liver function due to

any drug exposure or non-infectious agent. Incidence of Nevirapine induced hepatotoxicity was reported to be 16%<sup>(28)</sup> which is more common among women than men and in patients with higher CD4 T-cell counts. NNRTIs can cause hepatotoxicity in the first 2-3 months of therapy<sup>(29)</sup>. Mechanism of hepatic injury with Nevirapine is believed to be immunoallergic, since nevirapine has extensive hepatic metabolism and it acts as a substrate for CYP 2B6 and 3A4 and a potent inducer of these enzymes as well, results in liver injury<sup>(30)</sup>. Management includes early detection and removal of the offending agent along with adequate support care<sup>(31)</sup>.

#### **Nevirapine induced steven-johnson syndrome (hypersensitivity reactions)**

Steven Johnson syndrome (SJS) or Toxic epidermal necrolysis (TEN) is an immune complex hypersensitivity reaction which is variant of Erythema multiforme caused by many factors such as infections, drugs and malignancies. SJS is usually characterized by an extensive detachment of epidermis and erosions of mucous membranes<sup>(32, 33)</sup>. It has been reported that 0.3% of patients affected with SJS is due to Nevirapine<sup>(29)</sup>. The mechanism of this reaction is mostly unclear and postulated to involve drug specific cytotoxic lymphocytes and secretes IFN-gamma against the drug leads to drug induced rashes and also it has been observed that CD4+T cells depletion reduces as well as delays the severity of Nevirapine induced skin rashes<sup>(27)</sup>. Early diagnosis and withdrawal of offending agent is the initial step to be followed in treating Nevirapine induced SJS. Although the use of 2-week lead-in-dose of 200mg/day followed by 200mg twice a day may reduce the overall risk of rash, Corticosteroids and topical emollients can be used as a mainstay therapy for SJS. So, physicians should consider this fact before prescribing HAART while treating HIV patients<sup>(34, 35)</sup>.

#### **Protease inhibitors (PIs)**

Currently approved PIs by FDA include Areamprenavir, Etazanavir, Darunavir, Fosamprenavir, Indinavir, Lopinavir, Nelfinavir, Ritonavir, Saquinavir and Tipranavir<sup>(36)</sup>. They act as competitive inhibitors which directly bind to HIV protease enzyme, prevents subsequent cleavage of polypeptides<sup>(37)</sup>. Generally Lopinavir/Ritonavir

containing ART regimens is well tolerated. Common adverse effects include gastrointestinal effects, Lipohypertrophy, glucose intolerance<sup>(12)</sup>.

#### **Protease inhibitors induced lipodystrophy**

Lipodystrophy is characterized by abnormal or degenerative conditions of the body's adipose tissue, associated with metabolic changes including impaired glucose tolerance present in 15 -20% of patients with HIV infection and hyperlipidemia. It is more commonly seen in longstanding use of older PIs like Indinavir, Saquinavir and Lopinavir<sup>(16)</sup>. PIs induced Peripheral Lipodystrophy results from impaired CRABP1-mediated cis-9-retinoic acid stimulation of retinoid X receptor<sup>(38)</sup>. Effective management of protease inhibitor induced peripheral lipodystrophy includes withdrawal of the drug and switching to ART agents less likely to cause lipodystrophy. Darunavir and Atazanavir are the best choices if baseline hyperlipidemia is significant. All medications for diabetes such as insulin-sensitizing agents, Metformin and thiazolidinediones are recommended without dosage adjustment. Should encourage a healthy diet and regular exercise to reduce the fat accumulation and improve glucose and lipid abnormalities<sup>(12, 16)</sup>.

#### **HIV-1 entry inhibitors (fusion and ccr5 antagonist)**

Recent advances in the development of antiviral drugs include fusion inhibitors, which acts extracellularly to prevent the fusion of HIV to the CD4 or other target cell<sup>(37, 38, 39)</sup>. Enfuvirtide is a fusion inhibitor primarily used in patients with limited therapeutic options. However, it is not commonly used since it is a painful subcutaneous injection. Thus a second generation fusion inhibitor, Tifuvirtide has been developed which is more potent against HIV than Enfuvirtide. Common adverse effects include neutropenia and increased risk of pneumonia but have not been reported in any patients till date<sup>(12, 40)</sup>.

#### **CCR5 antagonist**

Maraviroc, an entry inhibitor, currently being used to treat patients with resistance to multiple HIV drugs that has been recently approved for the first-line HIV treatment regimens<sup>(41)</sup>. Maraviroc is better tolerated as well as effective as Efavirenz when combined with

Lamivudine/Zidovudine. It acts by preventing the entry of HIV into host cells by blocking the CCR5 co-receptor. Incidence of pruritis and vascular hypertensive disorders has been reported in 3.8% of the patients and Upper respiratory tract infections where also more common in Maraviroc recipients in the clinical trials<sup>(12, 42, 43)</sup>.

### Integrase inhibitors

Raltegravir and Elvitegravir were the drugs comes under the class of HIV-1 integrase inhibitors and sometimes referred as INSTI (Integrase Strand Transfer Inhibitor). Integrase inhibitors acts by blocking an HIV enzyme called integrase which prevents HIV from multiplying and can reduce the amount of HIV in the body. The possible adverse

effects caused by raltegravir are diaphoresis (4%) and pruritis in (2.3% to 6.7% of patients) whereas myopathy, rhabdomyolysis and muscle problems with muscle damage has been incidentally reported<sup>(43, 44, 45, 46, 47)</sup>.

### CONCLUSION

Antiretroviral therapy is becoming increasingly effective but also increasingly complex. Effective pharmaceutical care is required to manage the ADR'S which results from ART. Thus treating physicians and clinical pharmacists must remain aware of new and developing syndromes associated with Anti-retroviral therapy and clinical follow-up is required to manage the ADR associated with ART/HAART.

### REFERENCES

1. Jennifer L. Weinberg and Carrie L. Kovarik. The WHO clinical staging system for HIV/AIDS. *American Medical Association Journal of Ethics*. 2010; 12: 202-206.
2. Tirmizi SRH and Khan N. Mathematical analysis of side effects of HIV/AIDS medication. *Bangladesh Journal of Medical Science*. 2014; 13: 119-123.
3. Akshaya Srikanth.B, Chandrababu. S, Harlokesh Narayan Yadav and Sunil Kumar Jain. Incidence of Adverse Drug Reactions in human deficiency virus-positive patients using highly active antiretroviral therapy. *Journal of Advanced Pharmaceutical Technology and Research*. 2012; 3: 62-67.
4. Divakar.B, Mistry. S.D, Kantharia.N.D and Mamtarani. The study of Adverse Drug Reactions (ADR'S) in HIV patients taking highly active Anti-retroviral therapy in ART center, NCH, Surat, India. *International Journal of Medicine and Pharmaceutical Sciences*. 2012; 3: 9-18.
5. Lieketseng J Masenyeste, Samuel OM Manda and Henry G. Mw+ambi. An assessment of Adverse Drug Reactions among HIV positive patients receiving Anti-retroviral treatment in South Africa. *AIDS Research and Therapy*. 2015; 12: 1-8.
6. Martin Hartmann and Alexander Enk. Cutaneous effects of Anti-retroviral therapy. *Deutsches Arzteblatt International*. 2007; 104: A 1098-1103.
7. Chien-Ching Hung and Shan-Chwen Chang. Impact of highly active Anti-retroviral therapy on incidence and management of Human Immuno-deficiency Virus-related Opportunistic infections. *Journal of Antimicrobial Chemotherapy*. 2004; 54: 849-853.
8. Kartik.K Venkatesh and Kumarasamy N. Impact of Highly Active Anti-retroviral Therapy on ophthalmic manifestations in Human Immunodeficiency Virus/Acquired Immunodeficiency Syndrome. *International Journal of Ophthalmology*. 2008; 56: 391-393.
9. Valentina Montessori, Natasha Press, Marianne Harris, Linda Akagi and Julio S. G. Montaner. Adverse Effects of Anti-Retroviral Therapy for HIV infection. *Canadian Medical Association Journal*. 2004; 170: 229-238.
10. Sumith Bhatnagar, Himanshu Sharma and Sharma V.K. Study of adverse effects of Anti-Retroviral therapy in HIV naïve patients and their association with CD4 cell count. *Asian Journal of Pharmaceutical and Clinical Research*. 2013; 6: 122-123.
11. Languluri Reddenna, Shaik Ayub Basha, Donthu Venu Gopal and Tedlla Rama krishna. Highly Active Anti-Retroviral Therapy: incidence of adverse Drug Reactions. *International Journal of Allied Medical Sciences and Clinical Research*. 2013; 1: 25-30.

12. Carin E. Reust. Common adverse effects of anti-retroviral therapy for HIV disease. *American Academy of Family Physicians*. 2011; 83: 1443-1451.
13. Blake Max and Renslow Sherer. Management of the adverse effects of Anti-retroviral therapy and medication adherence. *Clinical Infectious Diseases*. 2000; 30: S96- 116.
14. Margaret Larrey, Abena Asante-Quashie, Ama Essel, Erest Kenu, Vincent Ganu and Alfred Neequaye. Adverse Drug Reactions to Anti-Retroviral Therapy using the early ART period at a tertiary hospital in Ghana. *Pan African Medical Journal*. 2014; 18: 1-6.
15. Emeka U. Ejeliogu et al., Zidovudine Induced Anemia in Human Immunodeficiency Virus infected children on Highly Active Anti-Retroviral Therapy in Jos, Nigeria. *Journal of Advances in Medical and Pharmaceutical Sciences*. 2014; 1: 1-10.
16. Catherine Orrell. Anti-retroviral Adverse Drug Reactions and their management. *Continuing Medical Education*. 2011; 29: 234-237.
17. Apollo James, Sudhakar.R, Ysaswini.B, Mani Malika. K, Ashok Kumar TR and Siva Kumar T. A case report on Zidovudine induced anemia and its management in HIV-1 infected patient. *International Journal of Pharmaceutical Sciences Review and Research*. 2014; 27: 67-68.
18. Byoung Chul Cho et al., A case of lactic acidosis caused by stavudine in an AIDS patient. *The Korean Journal of internal Medicine*. 2004; 19: 66-69.
19. Michele H. Mokrzycki, Carol Harris, Helen Mary, Jeffrey Laut, Joseph Palmisano. Lactic acidosis associated with Stavudine administration; a report of 5 cases. *Clinical Infectious Diseases*. 2000; 30: 198-200.
20. Bolhaar M.G and Karstardt A.S. A high incidence of Lactic Acidosis and symptomatic hyperlactatemia in women receiving Highly Active Anti-Retroviral Therapy in Soweto, South Africa. *Clinical Infectious Diseases*. 2007; 45: 254-260.
21. Hernsandez Perez E and Dawood H. Stavudine induced Hyperlactatemia/Lactic acidosis at a tertiary communicable disease in South Africa. *Journal of International Association Physicians in AIDS Care*.2010; 9: 109-112.
22. Plyush Omprakash Somani, Amol Khot, Samit Jain, Dharmesh Shah, Pravin Motilal Rathi. Stavudine induced multiple adverse effects in HIV-infected patient. *Journal of Case Reports*.2013; 3: 186-190.
23. Boubaker KMF et al., Hyperlactatemia in adults on anti-retroviral therapy: the Swiss HIV cohort study. *Clinical Infectious Diseases* .2001; 33: 1931-1940.
24. Sachin Kore and Waghmare C.S. Anti-retroviral therapy (ART)-induced lactic acidosis: A potentially life threatening but preventable complication in HIV/AIDS patients receiving Nucleoside Reverse Transcriptase Inhibitors (NRTIs). *Biomed Research-India*. 2012; 23:635-627.
25. Shubber Zara et al., Adverse events associated with Nevirapine and Efavirenz-based first-line Anti-retroviral Therapy: a systematic review and meta-analysis. *AIDS*. 2013; 27: 1403-1412.
26. Ana Blas-Garcia, Nadezta Apostolova and Juan V.Esplugues. Future perspectives in NNRTI-based therapy: basis for understanding their toxicity. *Recent Translational Research in HIV/AIDS*. 2011; 21: 275-294.
27. Danish Qureshi, Lokendra Dave and Ramakant Dixit. Steven Johnson Syndrome due to Nevirapine. *Indian Journal of Allergy, Asthma and Immunology*. 2014; 28: 49-51.
28. George I Eluwa, Titilope Badru and Kesiena J Akpoigbe. Adverse drug Reactions to Anti-Retroviral Therapy (ARVs): Incidence, type and risk factors in Nigeria. *BMC Clinical pharmacology* 2012; 12: 129.
29. Andrew Carr and David A Cooper. Adverse effects of Anti-Retroviral Therapy. *The Lancet*. 2000; 356: 1423-1430.
30. Radhakrishnan Rajesh, Sudha Vidyasagar, Subin Johnson, Sonika Singh and Shreekanth Sharma. Highly Active Anti-Retroviral Therapy induced cutaneous Adverse Drug Reactions in Patients with Human Immunodeficiency Virus infection. *International Journal of Pharmaceutical Sciences*. 2010; 2: 84-97.
31. Clinical and Research Information on Drug Induced Liver Injury ([livertox.nih.gov/resource.html](http://livertox.nih.gov/resource.html))
32. Ishan B. Patel, Shalini Adiga, Disha J. Shetty and Bairy.K.L. Nevirapine induced Stevens - Johnson syndrome: A case report. *International Journal of Basic and Clinical Pharmacology*. 2014; 3: 401-402.

33. Vijay Kumar Lakshman Lamani, Basavaraj C Kotinaot and Aruna Bhushan. Nevirapine induced Stevens - Johnson syndrome. *International Journal of Current Research and Academic Review*. 2015; 3: 156-158.
34. Swapnil S Deore, Rishikesh C Dandekar, Aarti M Mahajan and Vaishali V Shiledar. Drug induced-Stevens-Johnson Syndrome. *International Journal of Scientific Study* 2014; 2: 84-87.
35. Dona Kurian, Minu K.George, Neethu Ros Tom, Apollo James, Ashok Kumar TR and Siva Kumar T. Case report on Nevirapine induced Stevens - Johnson syndrome in HIV-1 infected patient. . *International Journal of Pharmaceutical Sciences Review and Research*. 2014; 24: 127-128.
36. Luciani Filippo, Cione Erika and Caroleomaria Cristiana. Monotherapy in HIV-1-infected adults: An update. *JSM Microbiology*. 2014; 2: 1-5.
37. Chris Rathbun R. Antiretroviral therapy for HIV infection.
38. (<http://emedicine.medscape.com/article/1533218-overview#a5>).
39. Suelen Jorge Souza, Liania Alves Luzia, Sigrid Sousa Santos and Patricia Helen Carvalho Rondo. Lipid profile of HIV-infected patients in relation to Anti-retroviral Therapy: A review. *Revista Da Associacao Medica Brasileira*. 2013; 59: 186-198.
40. Swapnil Subhash Bawage, Pooja Munnilal Tiwari, Shreekumar Pillai, Vida Dennis and Shree Ram Singh. Recent advances in Diagnosis, prevention, and treatment of Respiratory Syncytial Virus. *Advances in Virology*. 2011: 1-26
41. Louisc Profit. Maraviroc: The evidence for its potential in the management of HIV. *Proof of Concept Review*. 2007; 1-16.
42. Michael A. Lobritz, Annette N. Ratcliff and Eric J. Arts. HIV-1 entry, Inhibitors, and resistance. *Viruses*. 2010; 2: 1069-1105.
43. Yoav Keynan, Ethan Rubinstein, Ken Kasper and Keith R.Fowke. Maraviroc induced CCR5blockage for HIV infected individuals is associated with increased rates of Respiratory tract infections. *Virology and Mycology*, 2012; 1:1-3.
44. Borrás-Blasco, J, Navarro-Ruiz.A, Borrás.C and Casrera.E. Adverse cutaneous reactions associated with the newest antiretroviral drugs in patients with human immunodeficiency virus infection. *Journal of Antimicrobial Chemotherapy*. 2008; 62: 879-888.
45. Michael E. Abram et al., Impact of Primary Elvitegravir resistance- associated mutations in HIV-1 integrase on drug susceptibility and viral replication fitness. *Antimicrobial agents and Chemotherapy*. 2013; 57: 2654-2663.
46. Charles Hicks and Roy M. Gulick. Raltegravir: the first HIV types integrase inhibitor. *Clinical Infectious Diseases*. 2009; 48: 939-939.
47. Jurgen Kurt Bockstroh. Integrase inhibitors: why do we need a new drug class for HIV therapy. *European Journal of Medical Research*. 2009; 14: 1-3.
48. Rhabdomyolysis in a HIV-infected patient following the addition of raltegravir, a case report with review of the literature. *Journal of Clinical Research in HIV AIDS and Prevention*. 1: 58-63.

**How to cite this article:** Kandimalla.Chaitanya, Minu K. George, Bandlamudi.Yasaswini, Sudhakar.R, Anti-retroviral therapy induced adverse effects and its management: A brief review. *Int J of Allied Med Sci and Clin Res* 2015;3(3): 367-372.